Daratumumab
CR108435
Phase 3 small_molecule active
Quick answer
Daratumumab for Multiple Myeloma is a Phase 3 program (small_molecule) at Janssen Cilag International NV with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Multiple Myeloma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active